drugset / Trial / NCT01274455
Gene Therapy of Pancreatic Ductal Adenocarcinoma
Phase 1
Completed
22 enrolled
University Hospital, Toulouse
CAYLA-INVIVOGEN · collabClinical Research Center, Toulouse · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
NaSingle-groupOpen-labelTreatment
Summary
Near 85% of patients with pancreatic adenocarcinoma are diagnosed with a locally advanced and/or metastatic unresectable tumor. In these patients chemotherapy (such as gemcitabine) is given as a palliative therapy. Aim of the present study is to evaluate the feasibility, tolerance and antitumor effect of repeated intratumoral injection of a gene therapy product (with antitumor and chemo sensitizing effects) combined with gemcitabine in patients with unresectable pancreatic carcinoma.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYL-02 | Other / unclassified | 125 ug | Other |
| Subject | CYL-02 | Other / unclassified | 250 ug | Other |
| Subject | CYL-02 | Other / unclassified | 500 ug | Other |
| Subject | CYL-02 | Other / unclassified | 1 mg | Other |